Adial Pharmaceuticals appoints Tony Goodman as COO with $300K base salary, three-year term

ADIAL PHARMACEUTICALS, INC.

Tony Goodman appointed Chief Operating Officer effective April 1, 2025, under three-year employment agreement.
Base salary of $300,000 per year; eligible for discretionary bonus up to 30% of base.
Severance: six months for without-cause termination; 12 months if termination follows a change of control.
Goodman had been serving as COO since January 2024 via consulting agreement with The Keswick Group; that agreement terminates.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tony Goodman

Chief Operating Officer

ADIL · ADIAL PHARMACEUTICALS, INC.

Effective: 2025-04-01
Filed: March 21, 2025, 7:59 PM ET

On March 20, 2025, Adial Pharmaceuticals, Inc. (the “Company”) entered into an employment agreement with Tony Goodman (the “Goodman Employment Agreement”) to employ Mr. Goodman as the Company’s Chief Operating Officer for a three-year term effective April 1, 2025 (the “Effective Date”)

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tony Goodman was appointed as Chief Operating Officer at ADIAL PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On March 20, 2025, Adial Pharmaceuticals, Inc. (the “Company”) entered into an employment agreement with Tony Goodman (the “Goodman Employment Agreement”) to employ Mr. Goodman as the Company’s Chief Operating Officer for a three-year term effective April 1, 2025 (the “Effective Date”)

View on SEC.gov

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001013762-25-000999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.